Cargando…

A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer

Background: KRAS mutation, one of the most important biological processes in colorectal cancer, leads to poor prognosis in patients. Although studies on KRAS have concentrated for a long time, there are currently no ideal drugs against KRAS mutations. Methods: Different expression analysis and weigh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Kangjia, Song, Yanni, Guan, Zilong, Ou, Suwen, Ye, Jinhua, Ran, Songlin, Wang, Hufei, Tao, Yangbao, Gong, Zijian, Ma, Tianyi, Jin, Yinghu, Huang, Rui, Gao, Feng, Yu, Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237412/ https://www.ncbi.nlm.nih.gov/pubmed/35774610 http://dx.doi.org/10.3389/fphar.2022.899725

Ejemplares similares

Identification of the Crucial Role of CCL22 in F. nucleatum-Related Colorectal Tumorigenesis that Correlates With Tumor Microenvironment and Immune Checkpoint Therapy
por: Wang, Hufei, et al.
Publicado: (2022)

Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism
por: Ou, Suwen, et al.
Publicado: (2022)

Fusobacterium nucleatum upregulates MMP7 to promote metastasis-related characteristics of colorectal cancer cell via activating MAPK(JNK)-AP1 axis
por: Ou, Suwen, et al.
Publicado: (2023)

Characterization of endoplasmic reticulum stress unveils ZNF703 as a promising target for colorectal cancer immunotherapy
por: Wang, Hufei, et al.
Publicado: (2023)

Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts
por: Wang, Hufei, et al.
Publicado: (2022)

Identification pyroptosis-related gene signature to predict prognosis and associated regulation axis in colon cancer
por: Zhou, Kexun, et al.
Publicado: (2022)

Natural killer cell-related prognosis signature predicts immune response in colon cancer patients
por: Li, Meiqin, et al.
Publicado: (2023)

Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer
por: Lin, Bo, et al.
Publicado: (2020)

Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
por: Negrei, Carolina, et al.
Publicado: (2016)

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
por: Luo, Lian-Xiang, et al.
Publicado: (2017)

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
por: Xie, Chun, et al.
Publicado: (2017)

KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
por: Lin, Yu-Lin, et al.
Publicado: (2012)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2022)

Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway
por: Lai, Huanling, et al.
Publicado: (2018)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
por: Qi, Wenbo, et al.
Publicado: (2023)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

KRAS mutations are negatively correlated with immunity in colon cancer
por: Fu, Xiaorui, et al.
Publicado: (2020)

Vanillin Derivatives Reverse Fusobacterium nucleatum-Induced Proliferation and Migration of Colorectal Cancer Through E-Cadherin/β-Catenin Pathway
por: Zhou, Zhongkun, et al.
Publicado: (2022)

Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids
por: Fiore, Donatella, et al.
Publicado: (2018)

Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review
por: Wang, Ruiqi, et al.
Publicado: (2023)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
por: Zhong, Xi, et al.
Publicado: (2020)

Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer
por: Song, Xuesong, et al.
Publicado: (2022)

Comprehensive genomics analysis of aging related gene signature to predict the prognosis and drug resistance of colon adenocarcinoma
por: Feng, Jubin, et al.
Publicado: (2023)

Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
por: Guo, Libin, et al.
Publicado: (2022)

Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca(2+) overload-induced ferroptosis
por: Ni, Yinyun, et al.
Publicado: (2023)

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
por: Guo, Jun, et al.
Publicado: (2021)

N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer
por: Song, Yanni, et al.
Publicado: (2021)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
por: Hou, Xiaoying, et al.
Publicado: (2021)

Acrometastasis as the Initial Presentation of a KRAS-Positive Colon Cancer
por: Gharwan, Helen, et al.
Publicado: (2012)

A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response
por: Li, Chong, et al.
Publicado: (2023)

HIPPO signaling-related signature for predicting prognosis and therapeutic response in gastric cancer
por: Jiang, Rui, et al.
Publicado: (2023)

The functions and regulatory pathways of S100A8/A9 and its receptors in cancers
por: Zhou, Huimin, et al.
Publicado: (2023)

The effects of qishen granules for patients with chronic heart failure: A multicenter randomized double-blind placebo-controlled trial
por: Du, Kangjia, et al.
Publicado: (2022)

Thymopentin-Mediated Inhibition of Cancer Stem Cell Stemness Enhances the Cytotoxic Effect of Oxaliplatin on Colon Cancer Cells
por: Yu, Peng-Cheng, et al.
Publicado: (2022)

Immunological role and prognostic value of somatostatin receptor family members in colon adenocarcinoma
por: Yu, Xiaoqian, et al.
Publicado: (2023)

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
por: Abu-Sanad, Atlal, et al.
Publicado: (2015)

Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Shikonin in Colon Cancer
por: Chen, Yang, et al.
Publicado: (2020)

Is Curcumin at the Threshold of Therapeutic Effectiveness on Patients with Colon Cancer?—A Systematic Review
por: Shafei, Laila Khaled Ismael Abdelgawad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_102r5ui2r42klg9j4qgob6tlsu